Companies Merge to Form NeXstar

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 5
Volume 4
Issue 5

BOULDER, Colo--NeXagen, Inc. and Vestar, Inc. have merged to form NeXstar Pharmaceuticals, Inc. One focus of the new company will be the liposomal delivery of oligonucleotides. The company's initial product, AmBisome, is a liposomal formulation of amphotericin B, which has been approved for marketing in 16 countries for the treatment of life-threatening systemic fungal infections that fail to respond to conventional amphotericin B therapy.

BOULDER, Colo--NeXagen, Inc. and Vestar, Inc. have merged to formNeXstar Pharmaceuticals, Inc. One focus of the new company willbe the liposomal delivery of oligonucleotides. The company's initialproduct, AmBisome, is a liposomal formulation of amphotericinB, which has been approved for marketing in 16 countries for thetreatment of life-threatening systemic fungal infections thatfail to respond to conventional amphotericin B therapy.

A phase III trial of the product in conjunction with the NationalCancer Institute has recently been announced.

Articles in this issue
Genetic Therapy Gets NIH Patent
Fusion Product Delivers Potent Toxin to Malignant Cells
Retinoic Acid May Enhance Chemo In Ovarian Ca Cells
Compounds Block ras Gene Function Compounds Block ras Gene Function
Companies Merge to Form NeXstar
Scientists Debate Best Way to Spur Immune System to Battle Cancer: Interleukins or Altered Tumor Cells?
Antiangiogenesis Tested in Pediatric Tumors
Delivery of Effective Cyclophosphamide Metabolite Could Reduce Toxicity
New Director Attends Office of Alternative Medicine Advisory Meeting
Cancer Vaccine Made From Purified Tumor Antigen Enters Phase III Melanoma Trials
Worksite Cancer Screening Boosts Employee Morale
Centocor CA 125 II, New Version of CA 125 Assay, Is Now Available
Women Smokers Have High Nicotine Concentrations in Their Cervical Mucus
Ocean Organisms a Source of New Anticancer Drugs
House Wants to Cut NIH Budget
Recent Videos
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practice in the breast cancer field.
2 experts in this video
2 experts in this video
Related Content
Subgroup data from CARTITUDE-4 suggest that cilta-cel may overcome the poor prognosis associated with some high-risk features in multiple myeloma.

PFS, OS Improve With Cilta-Cel in R/R Multiple Myeloma Subgroups

Kristi Rosa
June 2nd 2025
Article

Subgroup data from CARTITUDE-4 suggest that cilta-cel may overcome the poor prognosis associated with some high-risk features in multiple myeloma.

Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Exploring Burnout Causes and Management in Oncologic Practice

Eric P. Winer, MD
June 2nd 2025
Podcast

Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Data from DESTINY-Breast09 may support trastuzumab deruxtecan plus pertuzumab as a frontline standard of care in HER2-positive advanced breast cancer.

Frontline T-DXd Combo Elicits Meaningful PFS in HER2+ Advanced Breast Cancer

Russ Conroy
June 2nd 2025
Article

Data from DESTINY-Breast09 may support trastuzumab deruxtecan plus pertuzumab as a frontline standard of care in HER2-positive advanced breast cancer.

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Ribociclib Offers Consistent Benefit in HR+ Early Breast Cancer Across All Ages and Menopausal Statuses

Ribociclib Offers Consistent Benefit in HR+ Early Breast Cancer Across All Ages and Menopausal Statuses

Gina Mauro
June 1st 2025
Article

Data from the phase 3 NATALEE trial confirms ribociclib plus NSAI consistently improves survival outcomes in stage II/III HR+/HER2– early breast cancer patients, regardless of age or menopausal status.

The safety profile of talquetamab continued to show a lower high-grade infection risk relative to other approved anti-BCMA bispecific antibodies.

Talquetamab Elicits Durable Responses, Survival in R/R Multiple Myeloma

Roman Fabbricatore
June 1st 2025
Article

The safety profile of talquetamab continued to show a lower high-grade infection risk relative to other approved anti-BCMA bispecific antibodies.